Literature DB >> 21684381

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.

Julia M L Brotherton1, Masha Fridman, Cathryn L May, Genevieve Chappell, A Marion Saville, Dorota M Gertig.   

Abstract

BACKGROUND: Australia introduced a human papillomavirus (HPV) vaccination programme with the quadrivalent HPV vaccine for all women aged 12-26 years between 2007 and 2009. We analysed trends in cervical abnormalities in women in Victoria, Australia, before and after introduction of the vaccination programme.
METHODS: With data from the Victorian Cervical Cytology Registry between 2003 and 2009, we compared the incidence of histopathologically defined high-grade cervical abnormalities (HGAs, lesions coded as cervical intraepithelial neoplasia of grade 2 or worse or adenocarcinoma in situ; primary outcome) and low-grade cytological abnormalities (LGAs) in five age groups before (Jan 1, 2003, to March 31, 2007) and after (April 1, 2007, to Dec 31, 2009) the vaccination programme began. Binary comparisons between the two periods were done with Fisher's exact test. Poisson piecewise regression analysis was used to compare incident rate trends.
FINDINGS: After the introduction of the vaccination programme, we recorded a decrease in the incidence of HGAs by 0·38% (95% CI 0·61-0·16) in girls younger than 18 years. This decrease was progressive and significantly different to the linear trend in incidence before introduction of the vaccination (incident rate ratio 1·14, 1·00-1·30, p=0·05). No similar temporal decline was recorded for LGAs or in older age groups.
INTERPRETATION: This is the first report of a decrease in incidence of HGAs within 3 years after the implementation of a population-wide HPV vaccination programme. Linkage between vaccination and screening registers is needed to confirm that this ecological observation is attributable to vaccination and to monitor participation in screening among vaccinated women. FUNDING: None.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21684381     DOI: 10.1016/S0140-6736(11)60551-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  127 in total

1.  The value of HPV vaccination.

Authors: 
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 2.  Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement.

Authors:  Debbie Saslow; Kimberly S Andrews; Deana Manassaram-Baptiste; Lacey Loomer; Kristina E Lam; Marcie Fisher-Borne; Robert A Smith; Elizabeth T H Fontham
Journal:  CA Cancer J Clin       Date:  2016-07-19       Impact factor: 508.702

3.  The road ahead for cervical cancer prevention and control.

Authors:  J E Tota; A V Ramana-Kumar; Z El-Khatib; E L Franco
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

4.  Practices and opinions regarding HPV vaccination among French general practitioners: evaluation through two cross-sectional studies in 2007 and 2010.

Authors:  Christine Lasset; Julie Kalecinski; Véronique Régnier; Giovanna Barone; Yann Leocmach; Philippe Vanhems; Franck Chauvin; Delphine Lutringer-Magnin
Journal:  Int J Public Health       Date:  2014-04-23       Impact factor: 3.380

Review 5.  Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review.

Authors:  A Ó Céilleachair; J F O'Mahony; M O'Connor; J O'Leary; C Normand; C Martin; L Sharp
Journal:  Qual Life Res       Date:  2017-06-26       Impact factor: 4.147

6.  Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program.

Authors:  Abbey B Berenson; Eneida Male; Toy G Lee; Alan Barrett; Kwabena O Sarpong; Richard E Rupp; Mahbubur Rahman
Journal:  Am J Obstet Gynecol       Date:  2013-11-23       Impact factor: 8.661

7.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.

Authors:  Jane J Kim; Emily A Burger; Stephen Sy; Nicole G Campos
Journal:  J Natl Cancer Inst       Date:  2016-10-18       Impact factor: 13.506

9.  Incidence of potentially human papillomavirus-related neoplasms in the United States, 1978 to 2007.

Authors:  George Kurdgelashvili; Graça M Dores; Samer A Srour; Anil K Chaturvedi; Mark M Huycke; Susan S Devesa
Journal:  Cancer       Date:  2013-04-11       Impact factor: 6.860

10.  Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls.

Authors:  Electra D Paskett; Jessica L Krok-Schoen; Michael L Pennell; Cathy M Tatum; Paul L Reiter; Juan Peng; Brittany M Bernardo; Rory C Weier; Morgan S Richardson; Mira L Katz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.